A Phase 1/2 interventional study of Pemetrexed - Phase 1 and Carboplatin - Phase 1 in Ovarian Cancer and Primary Peritoneal Cancer, sponsored by Eli Lilly and Company. Completed at 22 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-16.
Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing pemetrexed in Ovarian Neoplasms — none open to participants now, none under way, none of them phase 3. Pemetrexed · Ovarian Neoplasms.
Among the 13 studies testing pemetrexed in Ovarian Neoplasms, this one is the 2nd largest by enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2005, is the only one in phase 1/2, and was the 7th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →None of the 13 studies testing pemetrexed in Ovarian Neoplasms is open now. The open studies under Ovarian Neoplasms, anywhere →
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9
First in 2004; this study’s year is marked. 4 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 36 across the 12 interventional studies. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 13 have an industry lead sponsor. The 9 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
29 studies in Ovarian Neoplasms by Eli Lilly and Company: 6 open now, 9 under way, 1 of them phase 3. Of 19 finished, 12 (63%) have results posted.
Among the 29 studies in Ovarian Neoplasms by Eli Lilly and Company, this one is the 19th largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2005, is one of 3 in phase 1/2, and was the 14th registered.
Eli Lilly and Company’s Ovarian Neoplasms studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing pemetrexed in Ovarian Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 29 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine efficacy of the combination therapy of pemetrexed and carboplatin as treatment for patients with platinum-sensitive ovarian cancer. This study also includes patients with primary peritoneal cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
as defined by the (RECIST) guidelines, or non-measurable but cancer antigen 125 (CA-125) greater than or equal to 2X upper limit.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pemetrexed was administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle. Carboplatin was administered intravenously over approximately 30 minutes on Day 1 of a 21-day cycle, beginning approximately 30 minutes after the end of the pemetrexed infusion.
Drug: Pemetrexed - Phase 1 · Drug: Carboplatin - Phase 1
Pemetrexed was administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle. Carboplatin was administered intravenously over approximately 30 minutes on Day 1 of a 21-day cycle, beginning approximately 30 minutes after the end of the pemetrexed infusion.
Drug: Pemetrexed - Phase 2 · Drug: Carboplatin - Phase 2
500, 600, 700, 800, or 900 milligrams per square meter (mg/m\^2), administered intravenously (IV), every 21 days x 6 cycles, dose escalate to Maximum Tolerated Dose (MTD)
Also known as: LY231514, Alimta
area under the concentration time curve (AUC) 5 or 6 mg/mL\*min, administered intravenously (IV), every 21 days x 6 cycles, dose escalation to Maximum Tolerated Dose (MTD)
Dose determined from Phase 1: 500 mg/m\^2, administered IV, every 21 days x 6 cycles
Also known as: LY231514, Alimta
Dose determined from Phase 1: AUC 6 mg/mL\*min, administered IV, every 21 days x 6 cycles
Phase 1 - Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Carboplatin
MTD was to be determined by increasing doses of pemetrexed up to 900 mg/m\^2 and carboplatin Area Under the Concentration-Time Curve (AUC) up to 6 mg/mL\*min based on observed pattern of dose limiting toxicity (DLT). See Outcome #3 for DLT. If none of 3 initial participants at a given level experienced a DLT in Cycle 1, enrollment proceeded to the next dose level. If at least 2 participants experienced a DLT in Cycle 1 at a dose level, that dose level was considered the MTD. However, based on results from a different Phase 2 Study (NCT00109096), further dose escalations were not explored.
Time frame: First treatment to toxicity (up to 18 months)
Phase 2 - Percentage of Participants With Overall Tumor Response (Response Rate)
Response is defined as CR (Complete Response) or PR (Partial Response) per Response Evaluation Criteria in Solid Tumor (RECIST criteria). Possible evaluations include: CR: Disappearance of all target lesions. PR: At least a 30% decrease in the size of target lesions. Response rate (%) = (number of patients with CR+PR/number of patients in Phase 2)\*100
Time frame: baseline to measured progressive disease (PD) (up to 18 months)
Phase 1 - Number of Dose-Limiting Toxicities (DLTs)
The following toxicities were considered DLT: CTCAE Grade 4 neutropenia (absolute neutrophil count \[ANC\] \<0.5 × 10\^9/L lasting ≥7 days. Febrile neutropenia (ANC \<1.0 × 10\^9/L, fever 38.5°C, and no documented infection). CTCAE Grade 4 thrombocytopenia (platelets \<25.0 × 10\^9/L). Any hemorrhage with CTCAE Grade ≥3 thrombocytopenia (50.0 × 10\^9/L). CTCAE Grade ≥3 nonhematologic toxicity (excluding nausea, vomiting, or CTCAE Grade 3 alanine transaminase (ALT) or aspartate aminotransferase (AST) that returned to baseline prior to next treatment). Treatment delay more than 1 week due to toxicity.
Time frame: baseline through end of Phase 1 (up to 18 months)
Phase 1 - Number of Participants With Adverse Events (Toxicity)
A listing of adverse events is located in the Reported Adverse Event module.
Time frame: baseline measured to progressive disease (up to 18 months)
Phase 1 - Recommended Dose of Pemetrexed for Phase 2
MTD was to be used as Phase 2 recommended dose. MTD was to be determined by increasing doses of pemetrexed up to 900 mg/m\^2 based on observed pattern of dose limiting toxicity (DLT: See Outcome #3). If none of 3 initial participants at a given level had a DLT in Cycle 1, enrollment proceeded to next dose level. If at least 2 participants had a DLT in Cycle 1 at a dose level, that dose level was considered the MTD. However, based on results from another Phase 2 Study (NCT00109096), further dose escalations were not explored and dose was selected based on results of that Phase 2 Study.
Time frame: baseline measured to progressive disease (up to 18 months)
Phase 1 - Recommended Area Under the Curve (AUC) Dose of Carboplatin for Phase 2
MTD was to be used as Phase 2 recommended dose. MTD determined by increasing doses up to AUC 6 mg/mL\*min based on pattern of DLT (Outcome #3). If none of 3 initial participants at given level had DLT in Cycle 1, enrollment proceeded to next dose level. If at least 2 participants had DLT in Cycle 1 at dose level, that dose level was considered MTD. However, based on results from Phase 2 Study (NCT00109096), further dose escalations were not explored: carboplatin dose was selected based on standard dose employed in control arm of first-line therapy for epithelial ovarian cancer (Bookman 2006).
Time frame: baseline measured to progressive disease (up to 18 months)
Phase 1 - Number of Participants With Tumor Response
Patients were analyzed by Cancer Antigen-125 (CA-125) response criteria and RECIST guidelines. Possible evaluations include: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions. Progressive Disease (PD): At least a 20% increase in the size of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Time frame: baseline measured to progressive disease (up to 18 months)
Phase 2 - Time to Response (TTR)
Response is defined as CR (Complete Response) or PR (Partial Response) per RECIST criteria. Possible evaluations include: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions. Progressive Disease (PD): At least a 20% increase in the size of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Time frame: First treatment to response (up to 31 months)
Phase 2 - Duration of Response (DOR)
Duration of response is defined as the time from first observation of Complete Response or Partial Response to the first observation of Progressive Disease or death from any cause. For patients who are still alive at the time of analysis, and who do not have Progressive Disease, duration of response will be censored at the date of the last objective progression-free disease assessment.
Time frame: time of response to progressive disease (up to 31 months)
Phase 2 - Time to Disease Progression
Time to objective progressive disease (TTPD) is defined as the time from the date of study enrollment to the date of objectively determined Progressive Disease (PD). For patients who die without objective PD (including death from study disease), TTPD will be censored at the date of the last objective progression-free disease assessment. For patients who are still alive at the time of analysis, and who do not have PD, TTPD will be censored at the date of the last objective progression-free disease assessment.
Time frame: baseline to measured progressive disease (up to 31 months)
Phase 2 - Time to Treatment Failure
Time to treatment failure (TTTF) is defined as the time from the date of study enrollment to the date of the first observation of disease progression, death from any cause, or early discontinuation of treatment (any reason). For patients who are alive, progression-free, and have not discontinued early at the time of analysis, TTTF will be censored at the date of the last objective progression-free disease assessment.
Time frame: First treatment to discontinuation of study drug, progressive disease, or death (up to 31 months)
Phase 2 - Overall Survival
Overall survival is defined as the time from the date of study enrollment to the date of death from any cause. This analysis was not done due to the high number of censored patients.
Time frame: baseline to date of death from any cause (up to 31 months)
Phase 2 - Number of Participants With Adverse Events (Toxicity)
A listing of adverse events is located in the Reported Adverse Event module.
Time frame: baseline through end of Phase 2 (up to 31 months)
Phase 2 - Progression-Free Survival
Progression-free survival (PFS) is defined as the time from the date of study enrollment to the date of objectively determined PD or death from any cause, whichever comes first. For patients who are still alive at the time of analysis, and who do not have PD, PFS will be censored at the date of the last objective progression-free disease assessment.
Time frame: baseline to measured progressive disease (up to 31 months)
| Milestone | Pemetrexed/Carboplatin Phase 1 | Pemetrexed/Carboplatin Phase 2 |
|---|---|---|
| Started | 20 | 66 |
| Completed | 13 | 37 |
| Not completed | 7 | 29 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Progressive disease | 5 | 6 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 5 |
| Withdrew: Adverse event | 0 | 16 |
MTD was to be determined by increasing doses of pemetrexed up to 900 mg/m\^2 and carboplatin Area Under the Concentration-Time Curve (AUC) up to 6 mg/mL\*min based on observed pattern of dose limiting toxicity (DLT). See Outcome #3 for DLT. If none of 3 initial participants at a given level experienced a DLT in Cycle 1, enrollment proceeded to the next dose level. If at least 2 participants experienced a DLT in Cycle 1 at a dose level, that dose level was considered the MTD. However, based on results from a different Phase 2 Study (NCT00109096), further dose escalations were not explored.
No measurements were reported for this outcome.
Response is defined as CR (Complete Response) or PR (Partial Response) per Response Evaluation Criteria in Solid Tumor (RECIST criteria). Possible evaluations include: CR: Disappearance of all target lesions. PR: At least a 30% decrease in the size of target lesions. Response rate (%) = (number of patients with CR+PR/number of patients in Phase 2)\*100
| percentage of participants | Pemetrexed/Carboplatin Phase 2 |
|---|---|
| Phase 2 - Percentage of Participants With Overall Tumor Response (Response Rate) | 32.8 (21.3 to 46.0) |
The following toxicities were considered DLT: CTCAE Grade 4 neutropenia (absolute neutrophil count \[ANC\] \<0.5 × 10\^9/L lasting ≥7 days. Febrile neutropenia (ANC \<1.0 × 10\^9/L, fever 38.5°C, and no documented infection). CTCAE Grade 4 thrombocytopenia (platelets \<25.0 × 10\^9/L). Any hemorrhage with CTCAE Grade ≥3 thrombocytopenia (50.0 × 10\^9/L). CTCAE Grade ≥3 nonhematologic toxicity (excluding nausea, vomiting, or CTCAE Grade 3 alanine transaminase (ALT) or aspartate aminotransferase (AST) that returned to baseline prior to next treatment). Treatment delay more than 1 week due to toxicity.
| DLT events | Pemetrexed/Carboplatin Phase 1 |
|---|---|
| Number of DLT Events | 1 |
| DLT Event: Grade 4 Neutropenia | 1 |
A listing of adverse events is located in the Reported Adverse Event module.
| Participants | Pemetrexed/Carboplatin Phase 1 |
|---|---|
| Serious Adverse Events | 2 |
| Other Adverse Events | 19 |
MTD was to be used as Phase 2 recommended dose. MTD was to be determined by increasing doses of pemetrexed up to 900 mg/m\^2 based on observed pattern of dose limiting toxicity (DLT: See Outcome #3). If none of 3 initial participants at a given level had a DLT in Cycle 1, enrollment proceeded to next dose level. If at least 2 participants had a DLT in Cycle 1 at a dose level, that dose level was considered the MTD. However, based on results from another Phase 2 Study (NCT00109096), further dose escalations were not explored and dose was selected based on results of that Phase 2 Study.
| mg/m^2 (milligrams per square meter) | Pemetrexed/Carboplatin Phase 1 |
|---|---|
| Phase 1 - Recommended Dose of Pemetrexed for Phase 2 | 500 |
MTD was to be used as Phase 2 recommended dose. MTD determined by increasing doses up to AUC 6 mg/mL\*min based on pattern of DLT (Outcome #3). If none of 3 initial participants at given level had DLT in Cycle 1, enrollment proceeded to next dose level. If at least 2 participants had DLT in Cycle 1 at dose level, that dose level was considered MTD. However, based on results from Phase 2 Study (NCT00109096), further dose escalations were not explored: carboplatin dose was selected based on standard dose employed in control arm of first-line therapy for epithelial ovarian cancer (Bookman 2006).
| mg/mL*min | Pemetrexed/Carboplatin Phase 1 |
|---|---|
| Phase 1 - Recommended Area Under the Curve (AUC) Dose of Carboplatin for Phase 2 | 6 |
Patients were analyzed by Cancer Antigen-125 (CA-125) response criteria and RECIST guidelines. Possible evaluations include: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions. Progressive Disease (PD): At least a 20% increase in the size of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
| Participants | Pemetrexed/Carboplatin Phase 1 |
|---|---|
| Complete Response (CR) | 12 |
| Partial Response (PR) | 4 |
| Stable Disease (SD) | 1 |
| Progressive Disease (PD) | 2 |
Response is defined as CR (Complete Response) or PR (Partial Response) per RECIST criteria. Possible evaluations include: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions. Progressive Disease (PD): At least a 20% increase in the size of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
| Months | Pemetrexed/Carboplatin Phase 2 |
|---|---|
| Phase 2 - Time to Response (TTR) | 1.8 (1.4 to 2.8) |
Duration of response is defined as the time from first observation of Complete Response or Partial Response to the first observation of Progressive Disease or death from any cause. For patients who are still alive at the time of analysis, and who do not have Progressive Disease, duration of response will be censored at the date of the last objective progression-free disease assessment.
| Months | Pemetrexed/Carboplatin Phase 2 |
|---|---|
| Phase 2 - Duration of Response (DOR) | 9.1 (6.9 to 10.2) |
Time to objective progressive disease (TTPD) is defined as the time from the date of study enrollment to the date of objectively determined Progressive Disease (PD). For patients who die without objective PD (including death from study disease), TTPD will be censored at the date of the last objective progression-free disease assessment. For patients who are still alive at the time of analysis, and who do not have PD, TTPD will be censored at the date of the last objective progression-free disease assessment.
| Months | Pemetrexed/Carboplatin Phase 2 |
|---|---|
| Phase 2 - Time to Disease Progression | 9.5 (8.3 to 11.3) |
Time to treatment failure (TTTF) is defined as the time from the date of study enrollment to the date of the first observation of disease progression, death from any cause, or early discontinuation of treatment (any reason). For patients who are alive, progression-free, and have not discontinued early at the time of analysis, TTTF will be censored at the date of the last objective progression-free disease assessment.
| Months | Pemetrexed/Carboplatin Phase 2 |
|---|---|
| Phase 2 - Time to Treatment Failure | 7.1 (4.6 to 8.5) |
Overall survival is defined as the time from the date of study enrollment to the date of death from any cause. This analysis was not done due to the high number of censored patients.
No measurements were reported for this outcome.
A listing of adverse events is located in the Reported Adverse Event module.
| participants | Pemetrexed/Carboplatin Phase 2 |
|---|---|
| Serious Adverse Events | 15 |
| Other Adverse Events | 63 |
Progression-free survival (PFS) is defined as the time from the date of study enrollment to the date of objectively determined PD or death from any cause, whichever comes first. For patients who are still alive at the time of analysis, and who do not have PD, PFS will be censored at the date of the last objective progression-free disease assessment.
| Months | Pemetrexed/Carboplatin Phase 2 |
|---|---|
| Phase 2 - Progression-Free Survival | 9.4 (8.3 to 11.1) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed 500 + Carboplatin AUC 5 (Phase 1) | — | 1/4 (25%) | 4/4 (100%) |
| Pemetrexed 600 + Carboplatin AUC 5 (Phase 1) | — | 0/3 (0%) | 3/3 (100%) |
| Pemetrexed 600 + Carboplatin AUC 6 (Phase 1) | — | 0/4 (0%) | 4/4 (100%) |
| Pemetrexed 700 + Carboplatin AUC 6 (Phase 1) | — | 0/3 (0%) | 3/3 (100%) |
| Pemetrexed 800 + Carboplatin AUC 6 (Phase 1) | — | 1/3 (33.3%) | 3/3 (100%) |
| Pemetrexed 900 + Carboplatin AUC 6 (Phase 1) | — | 1/3 (33.3%) | 2/3 (66.7%) |
| Pemetrexed 500 + Carboplatin AUC 6 (Phase 2) | — | 15/66 (22.7%) | 63/66 (95.5%) |
| Event | Pemetrexed 500 + Carboplatin AUC 5 (Phase 1) | Pemetrexed 600 + Carboplatin AUC 5 (Phase 1) | Pemetrexed 600 + Carboplatin AUC 6 (Phase 1) | Pemetrexed 700 + Carboplatin AUC 6 (Phase 1) | Pemetrexed 800 + Carboplatin AUC 6 (Phase 1) | Pemetrexed 900 + Carboplatin AUC 6 (Phase 1) | Pemetrexed 500 + Carboplatin AUC 6 (Phase 2) |
|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/4 | 0/3 | 0/4 | 0/3 | 1/3 | 0/3 | 3/66 |
| ConstipationGastrointestinal disorders | 0/4 | 0/3 | 0/4 | 0/3 | 0/3 | 1/3 | 0/66 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/4 | 0/3 | 0/4 | 0/3 | 0/3 | 0/3 | 0/66 |
| Drug hypersensitivityImmune system disorders | 0/4 | 0/3 | 0/4 | 0/3 | 0/3 | 0/3 | 3/66 |
| VomitingGastrointestinal disorders | 0/4 | 0/3 | 0/4 | 0/3 | 0/3 | 0/3 | 2/66 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/4 | 0/3 | 0/4 | 0/3 | 0/3 | 0/3 | 2/66 |
| PancytopeniaBlood and lymphatic system disorders | 0/4 | 0/3 | 0/4 | 0/3 | 0/3 | 0/3 | 1/66 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/4 | 0/3 | 0/4 | 0/3 | 0/3 | 0/3 | 1/66 |
| TachycardiaCardiac disorders | 0/4 | 0/3 | 0/4 | 0/3 | 0/3 | 0/3 | 1/66 |
| Abdominal painGastrointestinal disorders | 0/4 | 0/3 | 0/4 | 0/3 | 0/3 | 0/3 | 1/66 |
| Event | Pemetrexed 500 + Carboplatin AUC 5 (Phase 1) | Pemetrexed 600 + Carboplatin AUC 5 (Phase 1) | Pemetrexed 600 + Carboplatin AUC 6 (Phase 1) | Pemetrexed 700 + Carboplatin AUC 6 (Phase 1) | Pemetrexed 800 + Carboplatin AUC 6 (Phase 1) | Pemetrexed 900 + Carboplatin AUC 6 (Phase 1) | Pemetrexed 500 + Carboplatin AUC 6 (Phase 2) |
|---|---|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 2/4 | 1/3 | 3/4 | 3/3 | 2/3 | 0/3 | 14/66 |
| ConstipationGastrointestinal disorders | 4/4 | 2/3 | 2/4 | 3/3 | 1/3 | 2/3 | 21/66 |
| NauseaGastrointestinal disorders | 4/4 | 2/3 | 3/4 | 3/3 | 3/3 | 2/3 | 42/66 |
| VomitingGastrointestinal disorders | 2/4 | 2/3 | 4/4 | 3/3 | 3/3 | 1/3 | 27/66 |
| FatigueGeneral disorders | 3/4 | 2/3 | 4/4 | 2/3 | 3/3 | 1/3 | 33/66 |
| HeadacheNervous system disorders | 2/4 | 3/3 | 3/4 | 1/3 | 1/3 | 2/3 | 5/66 |
| NeutropeniaBlood and lymphatic system disorders | 0/4 | 2/3 | 3/4 | 1/3 | 2/3 | 0/3 | 32/66 |
| StomatitisGastrointestinal disorders | 3/4 | 0/3 | 0/4 | 0/3 | 2/3 | 1/3 | 10/66 |
| Back painMusculoskeletal and connective tissue disorders | 3/4 | 0/3 | 2/4 | 0/3 | 1/3 | 0/3 | 2/66 |
| FlushingVascular disorders | 1/4 | 2/3 | 3/4 | 0/3 | 0/3 | 1/3 | 6/66 |
| Age Continuous(years) | Pemetrexed/Carboplatin Phase 1 | Pemetrexed/Carboplatin Phase 2 | Total |
|---|---|---|---|
| Mean | 56.99 ± 11.06 | 57.71 ± 10.44 | 57.54 ± 10.52 |
| Sex: Female, Male(Participants) | Pemetrexed/Carboplatin Phase 1 | Pemetrexed/Carboplatin Phase 2 | Total |
|---|---|---|---|
| Female | 20 | 66 | 86 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Pemetrexed/Carboplatin Phase 1 | Pemetrexed/Carboplatin Phase 2 | Total |
|---|---|---|---|
| Caucasian | 20 | 59 | 79 |
| Hispanic | 0 | 7 | 7 |
| Region of Enrollment(participants) | Pemetrexed/Carboplatin Phase 1 | Pemetrexed/Carboplatin Phase 2 | Total |
|---|---|---|---|
| Canada | 0 | 7 | 7 |
| Argentina | 0 | 14 | 14 |
| Poland | 0 | 5 | 5 |
| Germany | 20 | 31 | 51 |
| Sweden | 0 | 9 | 9 |
| Performance Status(participants) | Pemetrexed/Carboplatin Phase 1 | Pemetrexed/Carboplatin Phase 2 | Total |
|---|---|---|---|
| ECOG Status 0 | 3 | 46 | 49 |
| ECOG Status 1 | 17 | 20 | 37 |
| Tumor Type(participants) | Pemetrexed/Carboplatin Phase 1 | Pemetrexed/Carboplatin Phase 2 | Total |
|---|---|---|---|
| Ovarian Cancer | 15 | 61 | 76 |
| Peritoneal Cancer | 5 | 5 | 10 |
| Platinum-free interval(participants) | Pemetrexed/Carboplatin Phase 1 | Pemetrexed/Carboplatin Phase 2 | Total |
|---|---|---|---|
| <6 months | 0 | 3 | 3 |
| 6-12 months | 6 | 23 | 29 |
| >12 months | 14 | 40 | 54 |
The record gives a start of Jul 2005, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemetrexed